PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsAbatacept
Orencia(abatacept)
Orencia (abatacept) is a protein pharmaceutical. Abatacept was first approved as Orencia on 2005-12-23. It is used to treat juvenile arthritis, psoriatic arthritis, and rheumatoid arthritis in the USA. It has been approved in Europe to treat arthritis, psoriatic arthritis, and rheumatoid arthritis. The pharmaceutical is active against T-lymphocyte activation antigen CD80 and T-lymphocyte activation antigen CD86.
Download report
Favorite
BMS
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
musculoskeletal diseasesD009140
skin and connective tissue diseasesD017437
immune system diseasesD007154
Trade Name
FDA
EMA
Orencia
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Abatacept
Tradename
Proper name
Company
Number
Date
Products
OrenciaabataceptBristol Myers SquibbN-125118 RX2005-12-23
5 products
Labels
FDA
EMA
Brand Name
Status
Last Update
orenciaBiologic Licensing Application2025-11-13
Agency Specific
FDA
EMA
Expiration
Code
abatacept, Orencia, Bristol-Myers Squibb Company
2028-12-15Orphan excl.
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
L04: Immunosuppressants
L04A: Immunosuppressants
L04AA: Selective immunosuppressants
L04AA24: Abatacept
HCPCS
Code
Description
J0129
Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)
Clinical
Clinical Trials
325 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Rheumatoid arthritisD001172EFO_0000685M06.91215332355133
ArthritisD001168EFO_0005856M05-M14241173557
Kidney transplantationD01603041616530
Psoriatic arthritisD015535EFO_0003778L40.5122510
Graft rejectionD00608454110
Covid-19D000086382U07.1121115
Psychology rejectionD0120592114
Chronic kidney failureD007676EFO_0003884N18.621114
Delayed graft functionD0517991124
DermatomyositisD003882EFO_0000398M3311114
Show 12 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hepatitis bD00650922
HemorrhageD006470MP_0001914R5811
Heart failureD006333EFO_0003144I5011
MenorrhagiaD008595EFO_0003945N92.011
Hemophilia aD006467EFO_0007267D6611
PainD010146EFO_0003843R5211
Down syndromeD004314EFO_0001064Q9011
PneumoniaD011014EFO_0003106J1811
Mucocutaneous lymph node syndromeD009080EFO_0004246M30.311
HyperaldosteronismD006929E2611
Show 27 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameAbatacept
INNabatacept
Description
1-25-oncostatin M (human precursor) fusion protein with CTLA-4 (antigen) (human) fusion protein with immunoglobulin G1 (human heavy chain fragment), bimolecular (146-146')-disulfide
Classification
Protein
Drug classreceptor molecules or membrane ligands, natural, modified or modified: T-cell receptors
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Identifiers
PDB
CAS-ID
RxCUI
ChEMBL IDCHEMBL1201823
ChEBI ID
PubChem CID
DrugBankDB01281
UNII ID7D0YB67S97 (ChemIDplus, GSRS)
Target
Agency Approved
CD86
CD86
Organism
Homo sapiens
Gene name
CD86
Gene synonyms
CD28LG2
NCBI Gene ID
Protein name
T-lymphocyte activation antigen CD86
Protein synonyms
Activation B7-2 antigen, B-lymphocyte activation antigen B7-2, B70, BU63, CD86, CD86 antigen (CD28 antigen ligand 2, B7-2 antigen), CTLA-4 counter-receptor B7.2, FUN-1
Uniprot ID
Mouse ortholog
Cd86 (12524)
T-lymphocyte activation antigen CD86 (P42082)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
£
Orencia Bristol Myers Squibb
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 9,999 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
128,726 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use